

Press Release

Cyclopharma announces the acquisition of its French production facilities by the Curium Group. The development and commercialization of the most innovative molecules coming from Cyclopharma's pipeline will continue in a new company under the current Cyclopharma France and US management team.

Clermont-Ferrand (France), May 2nd 2018 – Cyclopharma, an innovative pharmaceutical company specialized in molecular imaging solutions, announces the acquisition of its French production facilities by Curium. The worldwide development and commercialization of molecules coming from Cyclopharma's pipeline will be pursued by a newly formed company, managed by the current Cyclopharma France and US management team.

Acquisition of Cyclopharma's french commercial activities by Curium

The divestiture of Cyclopharma's french commercial activities to Curium is now complete and will allow the Cyclopharma management to focus on the new company's mission of developing and commercializing best-in-class molecular imaging and therapy drugs. With this new organization, Cyclopharma is committed to provide patients and customers access to innovative diagnostic and therapeutic solutions.

Creation of a new company specialized in development and commercialization of molecules coming from Cyclopharma's pipeline

Cyclopharma's R&D programs, Cyclopharma US, and international development projects will be transferred to a new company owned by Denos, Cyclopharma's historical shareholder. The new company will pursue the development of compounds from Cyclopharma's pipeline in order to ensure their access to the market and their commercialization in France, the United States, and the rest of the world. The new company will continue to expand its presence in the United-States and in other parts of the world.

Olivier Carli, President of Denos, is particularly confident for the future: "We are creating a new company, focused on R&D and innovation. We will move forward, with our best-in-class molecule pipeline and we will contribute to write the future of Molecular Imaging, in France and worldwide. I want to thank all Cyclopharma's teams who are going to work with Curium from now on."

About Cyclopharma - cyclopharma.fr

Since its creation in 2000, Cyclopharma has developed molecular imaging solutions to allow the observation of cell function in vivo as part of the targeted treatment of cancer, in order to improve individualized treatment plans for patients in terms of diagnostics, monitoring and therapeutic effectiveness, whilst also reducing costs. With more than 110 employees and revenue of €23 million, Cyclopharma invests more than 10% of revenue in research into novel molecular imaging tracers. Since 2015 it has built on dense and balanced geographical coverage to drive international growth, with the aim of becoming a major European force in personalized medicine.

Contacts

Mathilde Bouscaillou
Communication Manager

+33 (0) 473 632 822
mbouscaillou@cyclopharma.fr